Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient. (June 2017)

• Record Type: Journal Article
• Authors: Lanzafame, Massimiliano; Lattuada, Emanuela; Nicolè, Stefano; Rigo, Fabio; Cucchetto, Giulia; Concia, Ercole; Vento, Sandro
• Is Part Of: International journal of STD & AIDS. Volume 28:Number 7(2017:Jul.)
• Page Start: 726
• Page End: 728
• Publication Date: 2017-06
• Subjects: Atazanavir -- dolutegravir -- pharmacokinetics -- maintenance antiretroviral therapy; Sexually transmitted diseases -- Periodicals; AIDS (Disease) -- Periodicals; 616.951
• DOI: 10.1177/0956462416678164
• Languages: English
• ISSNs: 0956-4624

Abstract

Highly active antiretroviral therapy (HAART) has changed the natural course of HIV infection. However, the toxicities associated with long-term use of nucleoside reverse transcriptase inhibitors (NRTIs) have led to the assessment of dual-therapy approaches with less toxicity. Atazanavir and dolutegravir have antiviral potency, tolerability and favourable metabolic profile. In suppressed HIV-infected patients, with NRTIs-related toxicity effects, the association of atazanavir and dolutegravir, favoured by their positive pharmacokinetics interaction, could be used as 'maintenance' antiretroviral therapy. We report a case report about one HIV-infected patient, on HAART and with a persistent suppression of HIV RNA, switched to dolutegravir 50 mg three times weekly plus atazanavir 400 mg once daily, as 'maintenance antiretroviral therapy', with persistence of viral suppression.